Regeneron and Sanofi’s Dupixent (dupilumab) Receives FDA’s Approval for Chronic Rhinosinusitis with Nasal Polyposis

 Regeneron and Sanofi’s Dupixent (dupilumab) Receives FDA’s Approval for Chronic Rhinosinusitis with Nasal Polyposis

Regeneron and Sanofi’s Dupixent (dupilumab) Receives FDA’s Approval for Chronic Rhinosinusitis with Nasal Polyposis

Shots:

  • The approval is based on two SINUS-24 & SINUS-52 studies results assessing Dupixent (300mg, q2w) + mometasone furoate nasal spray (MFNS) vs PBO + MFNS in patients with CRSwNP with uncontrolled disease
  • The SINUS-24 & 52 studies results: nasal congestion/obstruction improvement (57% & 51% vs 19% & 15%); reduction in nasal polyps score (33% & 27% vs 7% & 4%); improvement in sinus opacification (42% & 27% vs 4% & 0%); improvement in loss of smell (52% & 45% vs 12% & 10%); 83% reduction in surgery; 74% reduction in systemic corticosteroids administration
  • Dupixent (SC) is a mAb inhibiting the signals IL-4 & IL-13 available as pre-filled syringe, approved in EU, Japan & Australia for asthma and is under review in EU for CRSwNP & in Japan & EU for atopic dermatitis

Click here to read full press release/ article | Ref: Regeneron | Image: The Pike Company

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post